[2]Prevalence trends in non-alcoholic fatty liver disease at the global, regional and national levels, 1990-2017: a population-based observational study. BMJ Open . 2020 Aug 3;10(8):e036663. doi: 10.1136/bmjopen-2019-036663.
[3]The regulation of ApoB metabolism by insulin. Trends Endocrinol Metab . 2013 Aug;24(8):391-7. doi: 10.1016/j.tem.2013.04.001. Epub 2013 May 27.
[4]Cholesterol-induced non-alcoholic fatty liver disease and atherosclerosis aggravated by systemic inflammation. PLoS One. 2014 Jun 5;9(6):e97841. doi: 10.1371/journal.pone.0097841.
[5]Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis. World J Hepatol. 2015 Jun 8;7(10):1325-36. doi: 10.4254/wjh.v7.i10.1325.
[6]High-risk coronary plaque at coronary CT angiography is associated with nonalcoholic fatty liver disease, independent of coronary plaque and stenosis burden: results from the ROMICAT II trial. Radiology. 2015 Mar;274(3):693-701. doi: 10.1148/radiol.14140933.
[7]Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta-Analysis. Hepatology. 2019 Oct;70(4):1119-1133. doi: 10.1002/hep.30702.
[8]Epidemiological Features of NAFLD From 1999 to 2018 in China. Hepatology. 2020 May;71(5):1851-1864. doi: 10.1002/hep.31150.
[10]The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018 Jan;67(1):328-357. doi: 10.1002/hep.29367.
[11]Effect of Xuezhikang Capsule on serum tumor necrosis factor-alpha and interleukin-6 in patients with nonalcoholic fatty liver disease and hyperlipidemia. Chin J Integr Med.2010 Apr;16(2):119-23. doi: 10.1007/s11655-010-0119-7.
[12]Impact of long-term Xuezhikang therapy on cardiovascular events in high-risk patients with nonspecific, preexisting abnormal liver tests: a post-hoc analysis from Chinese Coronary Secondary Prevention Study (CCSPS). Int J Cardiol.2012 Feb 9;154(3):362-5. doi: 10.1016/j.ijcard.2011.11.005.
[13]Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver. World J Hepatol. 2020 Dec 27;12(12):1258-1266. doi: 10.4254/wjh.v12.i12.1258.
[14]Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J Hepatol. 2015 Jan;62(1):190-7. doi: 10.1016/j.jhep.2014.08.036.